|
Ganglioneuroma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, FUBP1 protein levels were remarkably increased with NB malignancy in the NB tissue microarray (NB: n = 65; ganglioneuroblastoma: n = 31; ganglioneuroma: n = 27).
|
31511046 |
2019 |
|
Schizophrenia
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia.
|
19165527 |
2009 |
|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.
|
28780352 |
2017 |
|
Ganglioneuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, FUBP1 protein levels were remarkably increased with NB malignancy in the NB tissue microarray (NB: n = 65; ganglioneuroblastoma: n = 31; ganglioneuroma: n = 27).
|
31511046 |
2019 |
|
Pancreatic carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrate that FUBP1 is overexpressed in pancreatic cancer and associated with poor prognosis.
|
30301530 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expressions of FUBP1 and c-Myc were both upregulated in ESCC tissues.
|
26490982 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The levels of FUBP1 mRNA and protein expression were upregulated in human ccRCC tissues compared with adjacent noncancerous tissues.
|
28076379 |
2017 |
|
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrate that FUBP1 is overexpressed in pancreatic cancer and associated with poor prognosis.
|
30301530 |
2018 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Supporting the clinical relevance of our results, we found that high levels of miR-16 and low or null FUBP1 expression correlate with TZ response in ErbB-2-positive primary BCs.
|
27157613 |
2016 |
|
Childhood Ganglioneuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, FUBP1 protein levels were remarkably increased with NB malignancy in the NB tissue microarray (NB: n = 65; ganglioneuroblastoma: n = 31; ganglioneuroma: n = 27).
|
31511046 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using fluorescent quantitative reverse transcription polymerase chain reaction (qPCR), the expression of FUBP1 mRNA was measured in colorectal cancer and its surrounding normal tissue from 32 patients.
|
25030436 |
2014 |
|
Sciatic Neuropathy
|
0.200 |
Biomarker
|
disease |
RGD |
FBP1 and p27kip1 expression after sciatic nerve injury: implications for Schwann cells proliferation and differentiation.
|
23939805 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FUBP1 is also described either as an oncoprotein or a tumor suppressor.
|
30343319 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, FUBP1 homozygous deletion was detected in one case suggesting a putative tumor suppressor role of FUBP1 in AOD.Our study showed that the genomic and pathological analyses of AOD are synergistic in detecting relevant clinical and biological subgroups of AOD.
|
23071531 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, we show that FUBP1 promotes tumor cell proliferation and migration and regulates the cancer cell immunity by increasing the PD-L1 expression mediated by Myc in pancreatic cancer cells.
|
30301530 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To date, all reported FUBP1 mutations have been predicted to inactivate FUBP1, which suggests that in contrast to most other tumours FUBP1 may act as a tumour suppressor in oligodendrogliomas.
|
24117486 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The trunk alterations that existed throughout the course were restricted to IDH1 mutation, 1p/19q-codeletion, and TERT promoter mutation, and mutation of the known candidate tumor suppressor genes CIC and FUBP1 were not consistently observed between primary and recurrent tumors.
|
28270234 |
2017 |
|
oligodendroglioma
|
0.080 |
Biomarker
|
disease |
BEFREE |
More recently described biomarkers, including the non-balanced translocation leading to 1p/19q codeletion, promoter hypermethylation of the MGMT gene, mutations of the IDH1 or IDH2 gene, and mutations of FUBP1 (on 1p) or CIC (on 19q), have greatly enhanced our understanding of oligodendroglioma biology, although their diagnostic, prognostic, and predictive roles are less clear.
|
25943885 |
2015 |
|
Well Differentiated Oligodendroglioma
|
0.080 |
Biomarker
|
disease |
BEFREE |
More recently described biomarkers, including the non-balanced translocation leading to 1p/19q codeletion, promoter hypermethylation of the MGMT gene, mutations of the IDH1 or IDH2 gene, and mutations of FUBP1 (on 1p) or CIC (on 19q), have greatly enhanced our understanding of oligodendroglioma biology, although their diagnostic, prognostic, and predictive roles are less clear.
|
25943885 |
2015 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our study identified the critical role of FUBP1-THBS1-TGF-β signaling axis in HCC and provides potentially new therapeutic modalities in HCC.
|
31587040 |
2019 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Targeting of FUBP1 in HCC therapy with SN-38/irinotecan could be a particularly interesting option because of the high FUBP1 levels in HCC cells and their dependency on FUBP1 expression.
|
29031818 |
2017 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53.
|
25995247 |
2015 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Moreover, we show that FUBP1 promotes tumor cell proliferation and migration and regulates the cancer cell immunity by increasing the PD-L1 expression mediated by Myc in pancreatic cancer cells.
|
30301530 |
2018 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The silencing of FUBP1 or the administration of a c-Myc inhibitor abrogated the cancer stem cell (CSC)-like characteristics induced by RARS-MAD1L1.
|
29133573 |
2018 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The scope of the present review is to describe the advances in our understanding of the molecular basis of FUBP1 functions in normal cells and carcinogenesis.
|
30343319 |
2019 |